Vigilance against drugs, malaria is the resistance required

Combination of current malaria therapies recommended by the World Health Organization (WHO), an appropriate treatment to facilitate malaria, after a Cochrane systematic review of evidence. However, studies have selected high rates for some combinations and evidence of the effectiveness of anti-malaria in some lack of therapy groups.

Malaria kills over one million people per year and over a third of public spending on public health in some countries seriously affected. Ease of malaria is a mild disease, but there may be serious and fatal if untreated. Resistance against former malaria, the WHO recommended treatment, a drug based on artemisinin with another drug longer fight against the resistance.

The review of 50 studies of association artemisinin-based therapies (ACTs). In total, four combinations were considered effective for treating the most common form of malaria parasites. The researchers conclude that the recently introduced dihydroartemisinin-piperaquine property in relation to acts, in use and offers a potential alternative courses of treatment.

Examples of non-compliance with the treatment of more than 10% for all combinations evaluated. This value is above the maximum rate allowed for a first line malaria drug, according to WHO recommendations.

"Model of the opposition to change the location to another and over time, so these results must be interpreted with some caution," says David Sinclair lead researchers from the Liverpool School of Tropical Medicine, Liverpool, UK. "Our results highlight the need for vigilance in monitoring of malaria and the development of drug resistance against malaria drugs."

In addition, there were few studies on the most vulnerable groups, pregnant women and young infants. "The absence of evidence of the use of these drugs in pregnant women and young children is a critical flaw in our knowledge, the question should be," says Sinclair.